Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity

Quince Therapeutics, a biotechnology company dedicated to acquiring, developing, and bringing innovative therapeutics to market, has recently announced its agreement to acquire EryDel SpA, a late-stage biotech company. This acquisition will involve an upfront exchange of stocks and potential cash payments based on future milestones. EryDel has made significant advancements in the field with thei..